Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LONA
SELLLeonaBio, Inc. · Healthcare · United States · $88M · Avg Vol: $200K/d
COMPANY DESCRIPTION
LeonaBio, Inc. is a clinical-stage biotechnology company focused on developing novel gene therapies for rare genetic diseases, leveraging cutting-edge advancements in gene editing and delivery platforms. The company aims to provide potentially curative treatments by directly addressing the root causes of genetic disorders. Its specialized focus on developing transformative therapies for underserved patient populations provides a competitive niche in the burgeoning gene therapy market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -10.20 | -12.56 | -10.47 | -24.70 | — | -24.09 |
| Shares | 9.4M | 9.4M | 9.4M | 9.3M | -0.6% | 9.4M |
| Debt | 1.9M | 1.6M | 1.2M | 0.8M | -25.1% | 0.7M |
| Equity | 235.1M | 130.2M | 44.8M | 27.8M | -50.9% | — |
| Op CF | -72.5M | -100.8M | -97.2M | -45.7M | — | -52.0M |
| Inv CF | 57.7M | 95.1M | 54.8M | -15.9M | — | — |
| Fin CF | 0.7M | 0.5M | 0.2M | 82.5M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LONA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LONA | LeonaBio, Inc.(you) | $88M | 33 | SELL |
| CUE | Cue Biopharma, Inc. | $107M | 33 | SELL |
| AGEN | Agenus Inc. | $126M | 33 | SELL |
| PTHS | Pelthos Therapeutics Inc. | $101M | 23 | SELL |
| ATRA | Atara Biotherapeutics, Inc. | $95M | 21 | SELL |
| ACOG | Alpha Cognition Inc. Common Stock | $142M | 29 | SELL |
| ACET | Adicet Bio, Inc. | $78M | 21 | SELL |
| VTVT | vTv Therapeutics Inc. | $138M | 27 | SELL |
| BOLD | Boundless Bio, Inc. | $58M | 41 | HOLD |
| FBIO | Fortress Biotech, Inc. | $92M | 49 | HOLD |
Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.5%